Stock comparison
United Therapeutics
UTHR$24.13BHealthcare Market cap, Sector
Vertex Pharmaceuticals
VRTX$110.28BHealthcare Market cap, Sector
Overall winner
United Therapeutics
UTHR 42 VRTX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
UTHR4wins
2winsVRTX
71B
C64
76B
C66
76B
B70
62C
C60
46D
D55
64C
C67
64C
C64
Side-by-side metrics
| Metric | UTHR | VRTX |
|---|---|---|
| Market cap | $24.13B | $110.28B Winner |
| P/E (TTM) | Winner: 19.2x | 25.6x |
| EV/EBIT | Winner: 15.2x | 22.6x |
| ROIC (TTM) | Winner: 18.81% | 17.74% |
| Gross margin | Winner: 86.58% | 86.28% |
| Net margin | Winner: 40.61% | 35.4% |
| Revenue CAGR 5y | Winner: 17.22% | 12.37% |
| EPS CAGR 5y | Winner: 29.84% | 14.2% |
| Debt / Equity | Winner: - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
UTHR leads on
- Debt / Equity-vs 0.1x+100%
- EPS CAGR 5y29.84%vs 14.2%+52%
- EV/EBIT15.2xvs 22.6x+33%
- Revenue CAGR 5y17.22%vs 12.37%+28%
VRTX leads on
- Market cap$110.28Bvs $24.13B+78%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.